Conference LibraryGated
Eur J Haematol 2026 · Salvage therapy with BCMA TCE + pomalidomide · Di Palma-Grisi/Parmar
"Multiple myeloma (MM) is a hematologic malignancy manifested by proliferation of clonal plasma cells leading to end-organ damage. Despite significant advancements in therapeutics, it remains incurable." Retrospective review of 12 patients (Jan 2024 - Dec 2025) on talquetamab / …
- Type
- paper
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_verify_wave_2_2026-05-16
- evidence_grade
- A
- category
- bcma_tce_salvage_clinical
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "small retrospective cohort (n=12) · not validated late-stage outcome · not intended to guide individual patient treatment choices · panel-level reference for ex vivo BCMA TCE sequencing context"
- journal
- European Journal of Haematology
- year
- 2026
- authors
- James Di Palma-Grisi,Harsh Parmar
- abstract_snippet
- "Multiple myeloma (MM) is a hematologic malignancy manifested by proliferation of clonal plasma cells leading to end-organ damage. Despite significant advancements in therapeutics, it remains incurable." Retrospective review of 12 patients (Jan 2024 - Dec 2025) on talquetamab
- pmid
- 41757804
- doi
- 10.1111/ejh.70151
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.